

ABSTRACT

Previous *in vitro* and *in vivo* studies have reported that 1'S-1'-acetoxychavicol acetate (ACA) and its analogue, 1'S-1'-acetoxyeugenol acetate (AEA) isolated from rhizomes of the Malaysian ethno-medicinal plant *Alpinia conchigera* Griff (Zingiberaceae) induces apoptosis-mediated cell death in tumour cells via dysregulation of the NF- κ B pathway and reduced physiological side effects on non-transformed cells. Nevertheless, there were some clinical development drawbacks such as poor solubility *in vivo*, depreciation of biological activity and non-specific targeting of tumour cells. In collaborative study with Institute of Engineering Immunology Russia, all the problems above were addressed using their novel drug conjugation technology involving a recombinant human alpha fetoprotein (rhAFP). However, in terms of future cost effectiveness, only ACA which is a major compound was selected for conjugation with rhAFP because AEA being a minor analogue, requires extensive purification steps with very low yield. As examined, thermodynamic studies showed that water soluble rhAFP was successful in retaining non-soluble forms of ACA within its hydrophobic pockets, hence acting as a chaperone which specifically targets tumour cells containing AFP surface receptors. This study also takes advantage of coupling ACA chemopotentiating effect and extrinsic pathway induction together with rhAFP's specificity and intrinsic pathway induction of apoptosis to increase the efficacy of drugs whilst maintaining a lower dose *per se*. To study the synergistic effect of both agents on human cancer xenografts, nude athymic (*Nu/Nu*) mice were used and treated with various combination regimes subcutaneously. It was found that mice exposed to combined treatments displayed higher reductions in tumour volume compared to standalone agents. In addition to this, combined drug treated mice also demonstrated milder signs of systemic toxicity, such as loss in body weight and inflammation of vital organs compared to

standalone treatments. The immunohistochemistry, ELISA and western blotting results also provided evidence that rhAFP/ACA was not only able to downregulate NF- κ B activation, but also reduced the expression of NF- κ B regulated genes and inflammatory biomarkers. Therefore, this drug conjugation technology shows great therapeutic potential and a pioneer for the basis of future combination anti-neoplastic drugs development.

ABSTRAK

Kajian *in vitro* dan *in vivo* terdahulu telah melaporkan bahawa 1'S-1'-acetoxychavicol acetate (ACA) dan analog nya, 1'S-1'-acetoxyeugenol acetate (AEA) yang diperolehi dari rizom tumbuhan etno-perubatan *Alpinia conchigera* Griff (Zingiberaceae) telah mendorong kematian sel-pengantara apoptosis dalam sel-sel tumor melalui penyahaktifan laluan signal NF- κ B dan mengurangkan kesan sampingan fisiologi pada sel-sel normal. Walau bagaimanapun, mereka mempunyai beberapa kelemahan dalam pengujian klinikal seperti kelarutan yang rendah dalam *in vivo*, penyusutan aktiviti biologi dan tidak mensasar secara spesifik kepada sel-sel tumor. Dalam kajian bersama Institut Kejuruteraan Immunologi Russia, semua masalah tersebut telah diatasi dengan menggunakan teknologi konjugasi yang melibatkan rekombinan alfa fetoprotein manusia (rhAFP). Walau bagaimanapun, dari segi keberkesanan kos pada masa hadapan, hanya ACA yang merupakan sebatian utama telah dipilih untuk dikonjugasi bersama rhAFP kerana AEA adalah analog kecil, memerlukan langkah-langkah pembersihan yang menyeluruh dengan hasil yang sangat rendah. Setelah diuji, kajian termodinamik menunjukkan bahawa rhAFP yang bersifat larut air telah berjaya mengekalkan bentuk tidak larut ACA di dalam poket hidrofobiknya yang bertindak sebagai 'chaperone' yang mensasar secara spesifik kepada sel-sel tumor yang mempunyai reseptor pada permukaan AFP. Kajian ini juga menggunakan kelebihan dari kesan gabungan ACA kimo-potensi dalam induksi laluan ekstrinsik bersama dengan rhAFP yang spesifik dalam rangsangan laluan intrinsik apoptosis untuk meningkatkan keberkesanan ubat, sementara mengekalkan dos '*per se*' yang lebih rendah. Untuk mengkaji kesan sinergi kedua-dua agen dalam 'xenografts' kanser manusia, tikus athymic (*Nu/Nu*) telah digunakan dan dirawat dengan pelbagai rejim gabungan secara suntikan 'subcutaneous'. Hasil kajian mendapati bahawa tikus yang dirawat secara rawatan

gabungan telah mempamerkan penurunan dalam jumlah pertumbuhan tumor berbanding dengan rawatan secara persendirian. Di samping itu, tikus yang dirawat secara rawatan gabungan juga menunjukkan tanda-tanda yang lebih rendah dalam ketoksikan sistemik, seperti kehilangan berat badan dan keradangan pada organ-organ penting, berbanding dengan rawatan secara persendirian. Keputusan immunohistochemistry, ELISA dan Western blot juga menunjukkan bahawa gabungan rhAFP/ACA bukan sahaja dapat menyahaktifkan laluan signal NF- κ B, tetapi juga mengurangkan ekspresi gen yang dikawal oleh NF- κ B serta 'inflammatory biomarkers'. Oleh yang demikian, teknologi konjugasi ini telah menunjukkan potensi terapeutik yang besar dan menjadi asas perintis bagi pembangunan gabungan ubat-ubatan 'anti-neoplastic' pada masa hadapan.

TABLE OF CONTENTS

	Page No
Abstract	ii
Abstrak	iv
Table of Contents	vi
Acknowledgements	xii
List of Figures	xiv
List of Tables	xxi
List of Abbreviation	xxii
Chapter 1: Introduction	1
1.1 Objectives	4
Chapter 2: Literature Review	5
2.1 Cancer	5
2.1.1 Oral Cancer (HSC-4 cell line)	7
2.1.2 Breast Cancer (MCF-7 cell line)	9
2.1.3 Lung Cancer (A549 cell line)	10
2.1.4 Prostate Cancer (PC-3 cell line)	11
2.2 Apoptosis	13
2.3 Natural Compounds	18
2.3.1 Sensitization by Plant Polyphenols to Chemotherapeutic Agents	21
2.3.2 <i>Alpinia conchigera</i> (Zingiberaceae)	24
2.3.3 1'S-1'-acetoxychavicol acetate (ACA)	27
2.3.4 1'S-1'-acetoxyeugenol acetate (AEA)	31

2.4	Alpha-fetoprotein (AFP)	34
2.5	Drug Conjugation in Clinical Practice	39
2.6	Nuclear Factor Kappa B (NF- κ B)	41
2.7	The NF- κ B Signaling Pathway in Inflammation and Cancer	46
2.8	Animal Model Studies	48
Chapter 3: Materials and Methods		54
3.1	Plant Material	54
3.1.1	Preparation of ACA and AEA Solutions	54
3.2	Cell Lines	55
3.2.1	Cell Lines and Cultivation of Cell Lines	55
3.2.2	Preparation of Frozen Stocks	56
3.2.3	Thawing of Cryopreserved Cells	56
3.2.4	Cell Counting	57
3.3	Migration Assay	58
3.4	Animal Model Studies I	58
3.4.1	Dehydration and Paraffinization of Tissue	60
3.5	Protein Expression Analyses	60
3.5.1	Immunohistochemistry (IHC)	60
3.6	Conjugation of ACA with Recombinant Human Alpha Fetoprotein (rhAFP)	61
3.6.1	Production and Isolation of the Recombinant Human Alpha Fetoprotein (rhAFP)	61
3.6.2	Preparation of Non-Covalent Complexes of the rhAFP with the ACA	63

3.7	Cytotoxicity Assays	63
3.7.1	Preparation of MTT Reagent	63
3.7.2	Cytotoxicity of the ACA and the rhAFP Standalone <i>In Vitro</i>	64
3.7.3	Cytotoxic Combination Effects of rhAFP/ACA Compositions <i>In Vitro</i>	65
3.7.4	Synergistic Enhancement of Tumour Growth Suppression Effects by Combined Treatment with rhAFP/ACA Complexes	65
3.8	Animal Model Studies II (<i>In vivo</i> Anti-tumour Efficacy of rhAFP/ACA Complexes)	66
3.8.1	Dehydration and Paraffinization of Tissue	68
3.9	Protein Expression Analysis	68
3.9.1	Immunohistochemistry (IHC)	68
3.9.2	Protein Extraction from FFPE Tissue	69
3.9.3	Protein Quantification and Normalization	69
3.9.4	PAGE Gels and Electrophoresis	70
3.9.5	Transfer of Proteins and Staining (Western Blotting)	72
3.10	Enzyme-Linked Immunosorbent Assay (ELISA)	73
3.11	Data Analysis	74
	Chapter 4: Results	76
4.1	ACA and AEA Suppresses the Proliferation and Migration Rate <i>In Vitro</i>	75
4.1.1	Percentage of Area Cells Migrated Between Treated and Untreated	76

4.2	ACA and AEA Increases the Efficacy of CDDP and Paclitaxel on HSC-4 and MCF-7 Xenografts <i>In Vivo</i>	76
4.2.1	Effects of ACA and CDDP <i>In Vivo</i>	77
4.2.2	Effects of AEA and Paclitaxel (Pac.) <i>In Vivo</i>	80
4.3	ACA and AEA Potentiate the Efficacy of CDDP and Paclitaxel <i>In Vivo</i> by Downregulating the NF- κ B Pathway and NF- κ B Regulated Genes	82
4.3.1	Histopathological Effects of ACA and CDDP on Tumour Biopsies	83
4.3.2	Histopathological Effects of AEA and Pac. on Tumour Biopsies	85
4.4	Conjugation of ACA with Recombinant Human Alpha Fetoprotein (rhAFP)	87
4.4.1	Formation of rhAFP/ACA Non-Covalent Complex	88
4.4.2	<i>In Vitro</i> Cytotoxicity of ACA and rhAFP Standalones	90
4.4.3	<i>In Vitro</i> Cytotoxic Effects of rhAFP/ACA Complex	92
4.4.4	Synergistic Enhancement of Tumour Growth Suppression Effects by Combination Treatment with rhAFP/ACA Complex	94
4.5	rhAFP/ACA Complex Potentiate the <i>In Vivo</i> Anti-tumour Effects on A549 Lung and PC-3 Prostate Cancer Cells	97
4.6	rhAFP/ACA Complex Mediates Anti-Cancer Effects through the NF- κ B Signalling Pathway	106
4.6.1	Effects of rhAFP/ACA Complex on NF- κ B Regulated Genes and Inflammatory Biomarkers in A549	106

	Lung Tumour Xenograft Biopsies	
4.6.2	Effects of rhAFP/ACA Complex on NF- κ B Regulated Genes and Inflammatory Biomarkers in PC-3 Tumour Xenograft Biopsies	120
4.6.3	Effects of rhAFP/ACA Complex on Additional NF- κ B Regulated Genes and Inflammatory Biomarkers in A549 and PC-3 Tumour Xenograft Biopsies	132
Chapter 5:	Discussion	135
5.1	Chemical Structure of ACA and AEA	137
5.2	Biological Correlation of ACA and AEA	139
5.3	ACA and AEA Suppresses the Proliferation and Migration Rate <i>In Vitro</i>	141
5.4	ACA and AEA Enhance the Efficacy of CDDP and Paclitaxel <i>In Vivo</i> by Downregulating the NF- κ B pathway and NF- κ B Regulated Genes	141
5.5	Conjugation of ACA with Recombinant Human Alpha Fetoprotein (rhAFP) as a Complex	144
5.6	<i>In vitro</i> and <i>In vivo</i> Cytotoxic Effects of rhAFP/ACA Complex	145
5.7	rhAFP/ACA Complex Mediates Anti-Cancer Effects through the NF- κ B Signalling Pathway	148

Chapter 6: Conclusion	151
References	153
Appendices	175
Appendix A: Solutions and Formulations	175
Appendix B: Immunohistochemistry (Paraffin)	177
Appendix C: Immunohistochemistry Troubleshooting Guide	178
Appendix D: DAB Peroxidase Substrate Solution – Brown	180
Appendix E: Original blot of Western results	181
Appendix F: Articles in Proceeding/Presented at Conference and Seminar	182

ACKNOWLEDGEMENT

In the name of Allah, most Gracious, most Merciful. I would like to express my sincere gratitude and deepest appreciation to my supervisor, Assoc. Prof. Dr. Noor Hasima bt. Nagoor Pitchai from Institute of Biological Sciences (Genetics & Molecular Biology), Faculty of Science, UM, for her continuous guidance, assistance and support during the process of the entire research. Her valuable help, wide knowledge and feedback given, was of great value to me.

Also special thanks to Dr. Lionel In Lian Aun for informative guidance during my initial start which was a follow up of his PhD project. His understanding, encouragement and patience provided me with valuable support.

I would also like to extend my gratitude to Prof. Khalijah Awang, Mr. Mohamad Nurul Azmi and Mr. Ahmad Nazif Aziz from Department of Chemistry, UM, for providing ACA and AEA used throughout this study and understanding the chemistry of these compounds.

Special thanks also to Prof. Dr. Elena Dudich and Dr. Eduard Tatulov from Biological System LLC, Institute of Immunological Engineering, Lyubuchany, Moscow, Russia, for providing the rhAFP protein and discussions on how to conjugate ACA with rhAFP for my PhD project.

I wish to express deep appreciation to Prof. Dr. Halijah Ibrahim from Department of Ecology and Biodiversity, ISB, UM, for suggestion of *Alpinia conchigera* as a potential anti-cancer plant.

Furthermore, I would also like to acknowledge University of Malaya Institutional Animal Care and Use Committee (IACUC) for giving me approval to carry out the animal

model experiments, and also special thanks to GIFT Sdn. Bhd. and Animal house UKM for helping me in the management of the mice in this study.

I would also like to forward my appreciation and thanks to all BGM-2 lab members for their patience, cooperation, teamwork, contribution and friendship.

Finally, my sincere appreciation and thanks is dedicated to my husband Muhammad Firdaus, my parents, family members and all my friends for their support and patience throughout this study.

Once again, thank you to all the people who have provided me with assistance in completing my study. Without the support and assistance from those mentioned, this project would not have been a success.

This study was funded by University Malaya (UM) through the Postgraduate Research Allocation (PPP) (PV043/2011A) and Ministry of Higher Education (MOHE) through the Fundamental Research Grant Scheme (FRGS) (FP024-2008C, FP031-2010A and KPT1060-2012). I would like to acknowledge and thank them for their generosity in terms of financing this project and making it a reality.

LIST OF FIGURES

		Page No
Figure 2.1	The hallmarks of cancer (Adapted from Hanahan & Weinberg, 2011).	6
Figure 2.2	Mechanisms of apoptosis (Adapted from Mondal & Dutta, 2014).	15
Figure 2.3	<i>Alpinia conchigera</i> Griff. (Adapted from Aziz <i>et al.</i> , 2013).	25
Figure 2.4	The order and classification of the <i>Alpinia</i> species up to section and subsection levels, according to Smith, 1990.	26
Figure 2.5	Chemical structure of ACA from <i>Alpinia conchigera</i> Griff. (Zingiberaceae), Malaysian isolates.	28
Figure 2.6	A proposed “Inhibition Model” depicting ACA mode of action on the canonical and non-canonical NF- κ B Pathway based in Western blotting results in HSC-4 cancer cells (Adapted from Lionel In, PhD thesis 2011).	30
Figure 2.7	Chemical structure of 1’S-1’-acetoxyeugenol acetate (AEA) from <i>Alpinia conchigera</i> Griff. (Zingiberaceae), Malaysian isolate.	31
Figure 2.8	A proposed ‘Switching/Alternating Model’ depicting 1’S-1’-acetoxyeugenol acetate (AEA) mode of action on the canonical and non-canonical nuclear factor κ B (NF- κ B) pathway based on Western blot results in MCF-7 cancer cells. IKK α , inhibitor of I κ B kinase α ; TNF, tumour necrosis factor (Adapted from In <i>et al.</i> , 2011).	33
Figure 2.9	Association of NF- κ B signaling pathway with tumourigenesis (Adapted from Aggarwal <i>et al.</i> , 2009).	44
Figure 2.10	Types of murine model for studying human cancers (Adapted from Richmond & Su, 2008).	50
Figure 2.11	Various xenograft models (Adapted from Jung, 2014).	53
Figure 4.1	Inhibition of migration rate by ACA and AEA as demonstrated using the wound healing assay with DMSO as solvent control. (A) HSC-4 cells treated with ACA (B) MCF-7 cells treated with AEA migration into wound area were captured at 0 h and 24 h compared	75

	with untreated (serum free media) and treated with DMSO at 100× magnification.	
Figure 4.2	Quantification of open wound areas after 24 h of incubation using the TScratch software. (A) The effects of ACA on HSC-4 cell migration (B) The effects of AEA on MCF-7 cell migration.	76
Figure 4.3	Reduction of tumour volumes when treated with ACA and CDDP in combination on <i>Nu/Nu</i> mice. (A) Photographs of <i>Nu/Nu</i> mice harvested 35 days post-implantation with human oral SCC (HSC-4) xenografts and 21 days post-treatment with various ACA/CDDP treatment regimes. Location of all tumour sites are indicated by closed arrows. (B) Representative photographs (<i>n</i> =5) of dissected oral tumours from different treatment regimes.	78
Figure 4.4	<i>In vivo</i> effects of ACA through assessment of <i>Nu/Nu</i> mice tumour volume and body weight after 35 days post-implantation and 21 days post-treatment. (A) Tumour volume regression between various ACA/CDDP treatments groups (B) Assessment on body weight loss between these various treatment groups.	79
Figure 4.5	Reduction of tumour volumes when treated with AEA and paclitaxel in combination on <i>Nu/Nu</i> mice. (A) Photographs of <i>Nu/Nu</i> mice harvested 28 days post-implantation with human breast adenocarcinoma cells (MCF-7) xenograft and 14 days post-treatment with various AEA/paclitaxel treatment regimes. Location of all tumour sites are indicated by closed arrows. (B) Photographs of dissected breast tumours from different treatment regimes.	80
Figure 4.6	<i>In vivo</i> effects of AEA through assessment of <i>Nu/Nu</i> mice tumour volume and body weight post-implantation across 35 days. (A) Tumour volume changes of MCF-7 xenograft mice treated with AEA, paclitaxel and AEA + paclitaxel. (B) Assessment on body weight loss between various AEA and paclitaxel treatment groups.	81
Figure 4.7	Histopathological effects of ACA and CDDP treatment on HSC-4 human oral squamous carcinoma xenograft tumour biopsies against members of the NF-κB and NF-κB regulated genes.	84

Figure 4.8	Quantification of IHC DAB staining on HSC-4 human oral SCC xenograft sections treated with various ACA and CDDP combination regime.	85
Figure 4.9	Histopathological effects of AEA and paclitaxel treatment on MCF-7 human breast adenocarcinoma xenograft tumour biopsies against members of the NF- κ B. Blue color indicates nuclei stained with hematoxylin and brown color indicates specific DAB antibody staining.	86
Figure 4.10	Quantification of IHC DAB staining on MCF-7 human breast adenocarcinoma xenograft sections treated with various AEA and paclitaxel combination regime.	87
Figure 4.11	Calorimetric scan of the intact ligand-free rhAFP, rhAFP/ACA complex and rhAFP after ligand removal. ACA removal drastically changes the melting pattern of rhAFP, while the addition of the ACA to rhAFP completely recovered the initial protein melting pattern which was characteristic of the intact rhAFP molecule	89
Figure 4.12	<i>In vitro</i> combined cytotoxic effects of rhAFP/ACA at various molar ratios after 24 h treatment against (A) A549 human lung, (B) PC-3 human prostate cancer cells and (C) HMEC human mammary epithelial non-cancerous cell control	93
Figure 4.13	Drug combination relationships between ACA and rhAFP over 24 h and 48 h suggesting the presence of a synergistic-type relationship. (A) Isobologram IC ₅₀ analysis on A549 human lung cancer cells, (B) Isobologram IC ₅₀ analysis on PC-3 human prostate cancer cells, (C) Isobologram IC ₅₀ analysis on HSC-4 human oral cancer cells and (D) Isobologram IC ₅₀ analysis on Ca Ski human cervical cancer cells.	95
Figure 4.14	Tumour reduction effects of various rhAFP/ACA treatment regimes on <i>Nu/Nu</i> mice. (A) Location of all surface tumour sites are indicated by closed arrows. (B) Representative photographs (n=6) of tumour harvested 35 days post-implantation with A549 human lung cancer xenografts and 28 days post-treatment with various rhAFP/ACA treatment regimes. (C) Tumour growth curve between various groups over a period of 9 weeks.(D) Assessment on tumour prevention properties of rhAFP/ACA.	99

Figure 4.15	Tumour reduction effects of various rhAFP/ACA treatment regimes on <i>Nu/Nu</i> mice. (A) Location of all surface tumour sites are indicated by closed arrows. (B) Representative photographs (n=6) of tumour harvested 35 days post-implantation with PC-3 human prostate cancer xenografts and 28 days post-treatment with various rhAFP/ACA treatment regimes. (C) Tumour growth curve between various groups over a period of 9 weeks. (D) Assessment on tumour prevention properties of rhAFP/ACA.	100
Figure 4.16	Signs of pulmonary inflammation and capillary haemorrhaging in CDDP treated groups and at high rhAFP/ACA ratio regimes ($\geq 1:3$) compared to placebo (A) A549 human lung and (B) PC-3 human prostate cancer xenografts.	101
Figure 4.17	Assessment on body weight loss between various combined rhAFP/ACA treatment groups on (A) A549 human lung and (B) PC-3 human prostate cancer xenografts. Placebo denotes groups treated with 0.9% (w/v) sodium chloride solution while concentration of CDDP was set at 10.0 mg/kg once per week over 8 weeks.	102
Figure 4.18	Weekly CEA tumour antigen marker levels from blood sera of Nude mice harbouring A549 human lung tumour xenografts upon treatment and pre-treatment with both standalone and rhAFP/ACA complex at various molar concentration ratios.	104
Figure 4.19	Weekly PSA tumour antigen marker levels from blood sera of Nude mice harbouring PC-3 human prostate tumour xenografts upon treatment and pre-treatment with both standalone and rhAFP/ACA complex at various molar concentration ratios.	105
Figure 4.20	Immunohistochemical analyses of the expression of p65 in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA-treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	107
Figure 4.21	Immunohistochemical analyses of the expression of COX-2 in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G)	109

rhAFP/ACA (1:5) treated group.

Figure 4.22	Immunohistochemical analyses of the expression of 5-LOX in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	110
Figure 4.23	Immunohistochemical analyses of the expression of VEGF in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	112
Figure 4.24	Immunohistochemical analyses of the expression of p21 in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	113
Figure 4.25	Immunohistochemical analyses of the expression of cleaved caspase-3 in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	115
Figure 4.26	Immunohistochemical analyses of the expression of HDAC2 in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	116
Figure 4.27	Immunohistochemical analyses of the expression of p300 in A549 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	118
Figure 4.28	Quantification of relative intensity of IHC DAB staining on A549 lung xenograft sections treated with various rhAFP/ACA combination regimes.	119

Figure 4.29	Immunohistochemical analyses of the expression of p65 in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	121
Figure 4.30	Immunohistochemical analyses of the expression of COX-2 in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	122
Figure 4.31	Immunohistochemical analyses of the expression of 5-LOX in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	123
Figure 4.32	Immunohistochemical analyses of the expression of VEGF in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	125
Figure 4.33	Immunohistochemical analyses of the expression of p21 in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	126
Figure 4.34	Immunohistochemical analyses of the expression of cleaved caspase-3 in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	127
Figure 4.35	Immunohistochemical analyses of the expression of HDAC2 in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	128

Figure 4.36	Immunohistochemical analyses of the expression of p300 in PC-3 tumour tissues derived from (A) placebo (B) CDDP treated group (C) ACA treated group (D) rhAFP treated group (E) rhAFP/ACA (1:1) treated group (F) rhAFP/ACA (1:3) treated group (G) rhAFP/ACA (1:5) treated group.	130
Figure 4.37	Quantification of relative intensity of IHC DAB staining on PC-3 prostate xenograft sections treated with various rhAFP/ACA combination regimes.	131
Figure 4.38	Western blotting analysis of CDK4 and MMP-9 in A549 lung tumour tissues derived from (A) placebo treated group, (B) CDDP treated group, (C) ACA standalone treated group, (D) rhAFP standalone treated group, (E) rhAFP/ACA 1:1 ratio treated group, (F) rhAFP/ACA 1:3 treated group and (G) rhAFP/ACA 1:5 ratio treated group. GAPDH control antibodies were used for normalization of band intensities.	133
Figure 4.39	Western blotting analysis of CDK4 and MMP-9 in PC-3 prostate tumour tissues derived from (A) placebo treated group, (B) CDDP treated group, (C) ACA standalone treated group, (D) rhAFP standalone treated group, (E) rhAFP/ACA 1:1 ratio treated group, (F) rhAFP/ACA 1:3 treated group and (G) rhAFP/ACA 1:5 ratio treated group. GAPDH control antibodies were used for normalization of band intensities.	134

LIST OF TABLES

		Page No
Table 3.1	Different types of human cancer cells used in this study, accompanied by the source and culture media used for cultivation.	56
Table 3.2	Treatment drug preparation guide for oral cancer treatments in male mice.	59
Table 3.3	Treatment drug preparation guide for breast cancer treatments in female mice.	60
Table 3.4	Summary of type, source and optimized dilution rate for primary antibodies used in IHC experiments.	61
Table 3.5	Treatment groups and doses used for assessment of various rhAFP/ACA combinations on <i>in vivo</i> Nude mice models.	67
Table 3.6	Summary of type, source and optimized dilution rate for primary antibodies used in IHC experiments.	68
Table 3.7	List of reagents used for the preparation of 7.5 %, 12.0 % resolving gel and a 4.0% stacking gel for SDS-PAGE.	71
Table 3.8	Summary of type, source and optimized dilution rates for primary and secondary antibodies used in Western blotting experiments.	73
Table 4.1	The thermodynamic effects of ligand-protein interaction on rhAFP heat melting parameters.	90
Table 4.2	The <i>in vitro</i> cytotoxic effects of ACA and rhAFP stand alone in various cancer and normal cell lines.	91
Table 4.3	Comparison between IC ₅₀ values of standalone ACA and combined rhAFP/ACA on various human cancer cell lines upon 48 hours exposure.	92

LIST OF ABBREVIATION

%	Percentage
(v/v)	Volume per Volume
(w/v)	Weight per Volume
±SD	Mean Standard Deviation
×	Times
®	Registered
μM	Micromolar
5-FU	5-Fluorouracil
5-LOX	5-Lipoxygenase
ACA	1'S-1'-acetoxychavicol acetate
ADC	Antibody Drug Conjugates
AEA	1'S-1'-acetoxyeugenol acetate
AFP	Alpha-fetoprotein
AFPR	Alpha-fetoprotein Receptor
APS	Ammonium Persulfate
AR	Androgen Receptor
ATP	Adenosine 5'-Triphosphate
AVMA	American Veterinary Medical Association
Bax	Bcl-2 Associated X Protein
Bcl-2	B-cell Lymphocyte 2
Bcl-X _L	B-cell Lymphocyte X _L
BD	Becton Dickenson
C	Carboxyl

CA	California
CAPE	Caffeic Acid Phenethyl Ester
CARIF	Cancer Research Initiative Foundation
Caspase	Cysteine Aspartate Protease
CBP	CREB Binding Protein
CBP	CBP-CREB Binding Protein
CDDP	Cisplatin
CDI	Coefficient Drug Interaction
CDK	Cyclin Dependent Kinases
CDK4	Cyclin Dependent Kinase 4
CEA	Carcinoembryonic Antigen
CI	Combination Index
cIAP-2	Cellular Inhibitor of Apoptotic Protein-2
CO ₂	Carbon Dioxide
COX-2	Cyclooxygenase-2
CTA	Cytotoxic activity
DAB	Diaminobenzidine
DASM	Differential Adiabatic Scanning Microcalorimetry
DMEM	Dulbecco's Modified Eagle's Medium
DMSO	Dimethyl Sulfoxide
DNA	Deoxyribonucleic Acid
DR	Doxorubicin
E3	E3 Ubiquitin Ligase
EBV	Epstein–Barr virus

EDTA	Ethylenediaminetetracetic Acid
EGFR	Epidermal Growth Factor Receptors
ELISA	Enzyme Linked Immunosorbent Assay
ERK	Extracellular-Signal Regulated Kinase
FBS	Fetal Bovine Serum
FDA	Food and Drug Administration
FFPE	Formalin-Fixed Paraffin Embedded
GEM	Genetically Engineered Mice
GSH	Glutathione Synthetase
H ₂ O ₂	Hydrogen Peroxide
HCl	Hydrochloric Acid
HDAC-2	Histone deacetylase
HEPA	High-Efficiency Particulate Air
HMEC	Human Mammary Epithelial Cells
HPLC	High- Performance Liquid Chromatography
HRP	Horseradish Peroxidase
Hrs	Hour
HSC-4	Human Squamous Carcinoma- Variant 4
i.p.	Intraperitoneal
IACUC	Institutional Animal Care and Use Committee
IAP	Inhibitors of Apoptotic Proteins
IC ₅₀	50% Inhibitory Concentration
IGF-IR	Insulin-Like Growth Factor I Receptors
IHC	Immunohistochemistry

IKK	IκB Kinase
IKK α	IκB Kinase Alpha
IKK β	IκB α Kinase Beta
IKK γ	IκB α Kinase Gamma
IKK ϵ	IκB α Kinase Epsilon
IL-4	Interleukin-4
IL-6	Interleukin-6
IL-8	Interleukin-8
ILAR	Institute of Laboratory Animal Resources
iNOS	Inducible Form of Nitric Oxide Synthase
IκB α	Inhibitor of Nuclear Factor Kappa B Alpha
kDa	Kilodalton
Kg	Kilograms
LPS	Lipopolysaccharides
MAP3K	MAP Kinase Kinase Kinases
MAPK	MAP Kinase
MDR	Multiple Drug Resistance
MEKK3	MAP Kinase/ERK Kinase Kinase Kinase Kinase
MeOH	Methanol
mg	Miligrams
mg/ml	Miligrams per Mililitre
Mins	minutes
ml	Mililitre
mm	Millimeter

mM	Milimolar
mm ³	Milimeter Cube
MMP-9	Matrix Metalloproteinase-9
MRP	Multidrug Resistance Protein
MTT	(3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide)
MW	Molecular Weight
NaCl	Sodium Chloride
NBF	Neutral Buffered Formalin
NCI	National Cancer Institute
NCR	National Cancer Registry
NEMO	NF-Kb Essential Modulator
NF-κB	Nuclear Factor Kappa B
NMR	Nuclear Magnetic Resonance
NPC	Nasopharyngeal Cancer
NSAID	Non-Steroidal Anti-Inflammatory Drugs
NSCLC	Non-Small Cell Lung Cancer
°C	Degree Celsius
<i>p</i>	<i>p</i> -value of Data Statistical Significance
PAGE	Polyacrylamide Gel Electrophoresis
PAMAM	Poly(amidoamine)
PARP	Poly [ADP-ribose] Polymerase
PBS	Phosphate Buffered Saline
PEC	Peritoneal Exudate Cells

PEC	Peritoneal Exudate Cells
PGP	P-glycoprotein
PGP	P-glycoprotein
pH	Potential of Hydrogen
PKB	Protein Kinase B
PLA ₂	Phospholipase A ₂
PSA	Prostate-Specific Antigen
PSA	Prostate Specific Antigen
PSMA	Prostate-Specific Membrane Antigen Negative
RCA	Replication Competent Adenoviruse
RES	Reticulo-Endothelial System
RES	Reticulo-Endothelial System
rhAFP	Recombinant Human Alpha Fetoprotein
RPMI	Rosewell Park Memorial Institute
s.c.	Subcutaneous
SCC	Squamous Cell Carcinoma
SCLC	Small Cell Lung Cancer
SCNC	Small Cell Neuroendocrine Carcinoma
SDS	Sodium Dodecyl Sulfate
SEM	Standard Error Mean
SPF	Specific Pathogen Free
SSD	Statistical Subdivision
STAT3	Signal Tranducer and Activator of Transcription 3
TAK1	Transforming Growth-Factor- β -Activated Kinase

TBS	Tris-Buffered Sakine
TEMED	N,N,N',N'-Tetramethyl-ethylenediamine
TGF	Transforming Growth-Factor
TGS	Tris-Glycine-SDS
TI	Tumour Implantation.
TMB	3.3', 5.5'-Tetramethylbenzidine
TNF	Tumour Necrosis Factor
TRAF	TNF Receptor-Associated Factors
USA	United State of America
UV	Ultraviolet
V	Volts
VEGF-A	Vascular Endothelial Growth Factor A
VGEF	Vascular Endothelial Growth Factor
Vol	Volume
WHO	World Health Organization
XIAP	X-linked Inhibitor of Apoptosis Protein
β	Beta
γ	Gamma
μ	Micro
$\mu\text{g/ml}$	Micrograms per Mililitre
μl	Microlitre